We found PDX1+/ALK3+/CAII− progenitor-like cells in the MPDs of types 1 and 2 diabetes donors, regardless of the duration of the disease. Our findings open the door to the pharmacological activation of progenitor cells in situ (PNAS)
Diabetes News
Category: Transplantation
Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study
Islet transplantation with the Edmonton protocol can provide 10-year markedly improved metabolic control without SHEs in three-quarters of patients with type 1 diabetes, kidney transplanted or not (Diabetes Care)
Biomarkers in Islet Cell Transplantation for Type 1 Diabetes
Recent advances in identifying accurate beta cell-specific biomarkers such as differentially methylated insulin cell-free DNA and circulating miRNA-375 may help predict clinical outcomes (Current Diabetes Reports)
Improved Insulin Sensitivity Appears to Remain for a Mean of Four Years Following Islet Cell Transplant for Type 1 Diabetes
IS measured by SIis was improved several years following transplant, while IS measured by HOMA-IR did not worsen. Higher exenatide dose, more islets transplanted, and diet and exercise (lowering leptin and RANKL) may improve IS, which may enhance glycemic control and lower metabolic demand on transplanted islets. Long-term clamp studies are needed to confirm these results (Diabetes/Metabolism Research and Reviews)
Who Should Be Considered for Islet Transplantation Alone?
The selection of appropriate candidates, optimizing donor selection, the use of an optimized protocol for islet cell extraction, and immunosuppression therapy have been proved to be the key criteria for a favorable outcome in islet transplantation (Current Diabetes Reports)
Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs … Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments would have been ineffective in preventing SHEs (Diabetes Care)
Diabetes Research Institute’s First Patient In BioHub Trial No Longer Requires Insulin Therapy
This was the first tissue engineered islet transplant using a ‘biodegradable scaffold’ implanted on the surface of the omentum (PR Newswire)
Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial
This was the first transplant of islets on the surface of the omentum, a highly vascularized tissue covering abdominal organs, using a biologic, fully re-absorbable scaffold technique (PR Newswire)
Current status of clinical islet transplantation
This brief overview presents recent progress in Islet transplantation. A concise historical perspective is provided, along with the latest efforts to improve islet engraftment, immune protection and ultimately, prolonged graft survival(World Journal of Transplantation)
Transplantation – the CIT07 Protocol & ß-Cell Secretory Capacity
These data indicate that engrafted islet ß-cell mass is markedly improved with the CIT07 protocol, especially given more frequent use of single islet donors. Although several peritransplant differences may have each contributed to this improvement, the lack of deterioration in ß-cell secretory capacity over time in the CIT07 protocol suggests that low-dose tacrolimus and sirolimus are not toxic to islets (Diabetes)
Glycosmedia is also available as an App: